Cenegermin Medicine 09 January 2018 Extended indication Neurotrofische keratitis. Therapeutic value No judgement Total cost Registration phase Unknown Product Active substance Cenegermin Domain Neurological disorders Reason of inclusion Main indication Eye disorders Extended indication Neurotrofische keratitis. Current proprietary name Already available biosimilars / generics Proprietary name Oxervate Manufacturer Dompé Portfolio holder Mechanism of action Unknown Route of administration Ocular Therapeutical formulation Eye drops Budgetting framework Extramural (GVS) Centre of expertise Additional remarks Werkingsmechanisme: 'Recombinant human nerve growth factor (rhNGF)'. Registration Registration route Centralised (EMA) Type of trajectory Accelerated assessment Particularity Unknown ATMP Unknown Submission date December 2016 Expected Registration July 2017 Orphan drug Yes Registration phase Unknown Reimbursement Medicine sluice Additional remarks Oxervate geregistreerd bij de EMA voor Keratitis. Therapeutic value Current treatment options Therapeutic value No judgement This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration Dosage per administration References Additional remarks Expected patient volume per year Patient volume < 7,140 Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References EMA Additional remarks Neurotrophic keratitis affected approximately 4.2 in 10,000 people in the European Union (EU). Dit zijn 7.140 patienten per 17M Nederlanders.' (EMA) Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks